Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451328 | 0.92 | IDH1 (0.47) | CYP19A1GAAMGAMSIMGAM2 | |
| SCHEMBL6454678 | 0.86 | CYP19A1 (0.42) | CYP19A1GAAMGAMSIMGAM2 | |
| SCHEMBL6453914 | 0.86 | HSD17B2 (0.40) | CYP19A1GAAMGAMSIMGAM2 | |
| SCHEMBL6449813 | 0.84 | KDM4E (0.41) | GAANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL6456605 | 0.84 | CASP6 (0.38) | NPC1ALDH1A1IDO1SPR | |
| SCHEMBL6454166 | 0.84 | CYP19A1 (0.42) | CYP19A1ALDH1A1IDO1SPRTLR8 | |
| SCHEMBL6450015 | 0.83 | CYP19A1 (0.49) | CYP19A1GAANPC1IDH1ALDH1A1 | |
| SCHEMBL6452679 | 0.82 | MAPT (0.43) | CYP19A1GAANPC1KDM4EHPGD | |
| SCHEMBL6448670 | 0.79 | MAPT (0.44) | GAANPC1ALDH1A1KDM4EIDO1 | |
| SCHEMBL6449876 | 0.78 | CYP3A4 (0.44) | NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | CYP19A1 523/4885GAA 519/4885MGAM 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.